Long-term intervention studies using insulin in patients with type 1 diabetes.

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Geremia B Bolli

Abstract

To discuss data from long-term intervention studies regarding therapy in type 1 diabetes and review strategies for preventing hypoglycemia and safely achieving glycemic goals in this patient population. The shortcomings of traditional models of insulin therapy are elucidated, and the need for physiologic insulin replacement is emphasized. An estimated more than 10 million patients will have type 1 diabetes worldwide within the next 20 years. Twice-daily injection of premixed or self-mixed insulin is the most common insulin regimen; however, this therapeutic strategy is also a major contributor to hypoglycemia and, eventually, hypoglycemia unawareness. Hypoglycemia unawareness in patients with type 1 diabetes has been found to be largely reversible. Moreover, intensive insulin therapy may prevent hypoglycemia and maintain glycemic targets. The most physiologic regimen of insulin available is continuous subcutaneous insulin infusion with an insulin pump; however, insulin glargine is a useful alternative to pump therapy. Use of today's rapid- and long-acting insulin analogues in intensive management protocols not only improves glycemic control but also reduces the risk of hypoglycemia. Therefore, safe achievement and maintenance o...Continue Reading

References

Oct 1, 1985·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·G Dimitriadis, J Gerich
Jun 28, 1984·The New England Journal of Medicine·G B BolliJ E Gerich
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
May 22, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Resea

❮ Previous
Next ❯

Citations

Feb 24, 2007·Diabetes Technology & Therapeutics·Reinhard H A Becker
Aug 31, 2006·Diabetes Technology & Therapeutics·N G LessanS Athamneh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Related Papers

The New England Journal of Medicine
G Gwinup, A N Elias
Diabetes Technology & Therapeutics
Satish K Garg
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Allan A Vaag
© 2022 Meta ULC. All rights reserved